BioSpace News Archive

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Candel Therapeutics, Inc. today announced the appointment of three new members to its Board.

Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel drug delivery approaches, today announced the presentation of a study entitled, “Treatment of Alzheimer’s disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb.”

Gracell Biotechnologies Inc. today announced the appointment of Wendy Li, M.D., as its Chief Medical Officer (CMO).

Structure Therapeutics Inc. (Structure Therapeutics), formerly known as ShouTi Inc., today announced it closed an oversubscribed $33 million financing round, extending its $100 million Series B financing, which was announced in October 2021.

Amphera B.V., a late-stage biotechnology company developing cell therapies to treat cancer, announces that the last patient has completed the active follow-up in the Phase II/III DENIM study of MesoPher cell therapy to treat pleural mesothelioma.

Nuvation Bio Inc. today announced that it will prioritize NUV-868 and development of its novel small molecule DDC platform and discontinue clinical development of NUV-422.

Carterra, Inc. and La Jolla Institute for Immunology (LJI) announced today that LJI has acquired a Carterra LSA instrument to enhance its antibody screening and characterization work.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the Company will host a business update conference call on Monday, August 15, 2022, at 4:30 PM EDT.

Catalyst Biosciences, Inc. published a detailed investor presentation in advance of its upcoming 2022 Annual Meeting of Stockholders, scheduled to be held on August 15, 2022.